Evidence map›Paper›PMID 37474764›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2023

High carriage rate of extended-spectrum β-lactamase Enterobacterales and diarrheagenic Escherichia coli in healthy donor screening for fecal microbiota transplantation.

Chien Chuang, Kuei-Chuan Lee, Yen-Po Wang, Pei-Chang Lee, Tien-En Chang, Yi-Hsiang Huang, Yi-Tsung Lin, Ming-Chih Hou

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Frontiers in immunology · 2026
    Article
  3. Article
  4. Outcomes of Fecal Microbiota Transplantation forOpen forum infectious diseases · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Przeglad gastroenterologiczny · 2024
    Review
  12. Assuring safety of fecal microbiota transplantation in the COVID-19 era: A single-center experience.JGH open : an open access journal of gastroenterology and hepatology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chien ChuangDivision of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Kuei-Chuan LeeSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Yen-Po WangSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Pei-Chang LeeSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Tien-En ChangSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Yi-Hsiang HuangSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Yi-Tsung Lin *Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. ytlin8@vghtpe.gov.tw.ORCID http://orcid.org/0000-0003-4466-8486
Ming-Chih Hou *School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. mchou@vghtpe.gov.tw.
National Yang Ming Chiao Tung University · TW

Funding

Taipei Veterans General Hospital V107E-007-1 (108)Taipei Veterans General Hospital V108E-007-1 (108)Taipei Veterans General Hospital V108E-007-1 (109)Taipei Veterans General Hospital V110E-002-1
6 · The paper itself

Abstract

The safety of fecal microbiota transplantation (FMT) has been highlighted by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli bacteremia transmitted from donors and acquisition of diarrheagenic E. coli (Shiga toxin-producing E. coli (STEC) and enteropathogenic E. coli (EPEC)) via FMT. The use of donor screening criteria to lower the risk of pathogen transmission via FMT is essential. This study aimed to demonstrate the outcomes of our strict donor screening program. This study was conducted at our FMT center between January 2019 and June 2022. Our donor screening program included an initial questionnaire and subsequent blood and stool testing. We further used selective culture for third-generation cephalosporin-resistant (3GCR) Enterobacterales and multiplex PCR to detect diarrheagenic E. coli in stools. The resistance mechanisms and sequence type of 3GCR Enterobacterales were determined. A total of 742 individuals were assessed, and 583 participants (78.6%) were excluded after questionnaire. Of the remaining 159 participants undergoing stool and blood tests, 37 participants were finally qualified (5.0%, 37/742). A high fecal carriage rate of ESBL-producing Enterobacterales (35.2%, 56/159), including E. coli (n=53) and Klebsiella pneumoniae (n=5), and diarrheagenic E. coli (31.4%, 50/159), including EPEC (n=41), enteroaggregative E. coli (n=11), enterotoxigenic E. coli (n=4), and STEC (n=1), was noted. CTX-M-79 and CTX-M-15 were dominant in E. coli and K. pneumoniae, respectively. The sequence types of the ESBL-producing strains were diverse. The screening for 3GCR Enterobacterales and diarrheagenic E. coli in stool is necessary. Our findings also support the effectiveness of multiplex PCR panels in FMT donor screening programs.

Indexed as

Escherichia coliEscherichia coli InfectionsAnti-Bacterial Agentsbeta-LactamasesDonor SelectionFecal Microbiota TransplantationFecesHumansKlebsiella pneumoniaeMicrobial Sensitivity TestsAnti-Bacterial Agentsbeta-LactamasesDiarrheagenic Escherichia coliDonors for fecal microbiota transplantationExtended‐spectrum β‐lactamase EnterobacteralesFecal carriage

Identifiers

PMID37474764
OpenAlexW4384925835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.